ALAB vs CPAY
Astera Labs vs Corpay — AI-powered side-by-side comparison
| Metric | ALAB | CPAY |
|---|
| AI Score |
64
|
71
|
| Price |
$317.37
|
$402.34
|
| P/E Ratio |
154.00×
|
23.60×
|
| ROE |
16.1%
|
27.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.1%
|
73.3%
|
| Debt / Equity |
0.00×
|
2.35×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
54.2
|
61.8
|
| Beta |
3.843
|
0.869
|
| Expected Upside |
+49.3%
|
+1.9%
|
AI Committee View
Current Innellis committee reasoning for ALAB versus CPAY.
CPAY leads by 7 points.
CPAY scores 71/100 (Buy) versus ALAB at 64/100 (Buy).
ALAB Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 25.2% shows genuine earnings power backing the valuation — Value
- Revenue growing 98.5% YoY -- genuine top-line momentum — Growth
- EPS growing 254.9% YoY — Growth
Bear Case
- P/E of 156.9 is expensive by classic value standards — Value
- Price-to-book of 20.6x prices in significant intangible value — Value
- Bollinger bandwidth of 39.0% signals elevated volatility — Risk
CPAY Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Risk/reward is unfavorable: 14.7% downside vs 1.9% upside.